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Abstract
Background: Pandemic influenza A(H1N1) 2009 virus was first detected in Japan in May 2009 and continued to circulate in
the 2010–2011 season. This study aims to characterize human influenza viruses circulating in Japan in the pandemic and
post-pandemic periods and to determine the prevalence of antiviral-resistant viruses.
Methods: Respiratory specimens were collected from patients with influenza-like illness on their first visit at outpatient
clinics during the 2009–2010 and 2010–2011 influenza seasons. Cycling probe real-time PCR assays were performed to
screen for antiviral-resistant strains. Sequencing and phylogenetic analysis of the HA and NA genes were done to
characterize circulating strains.
Results and Conclusion: In the pandemic period (2009–2010), the pandemic influenza A(H1N1) 2009 virus was the only
circulating strain isolated. None of the 601 A(H1N1)pdm09 virus isolates had the H275Y substitution in NA (oseltamivir
resistance) while 599/601 isolates (99.7%) had the S31N substitution in M2 (amantadine resistance). In the post-pandemic
period (2010–2011), cocirculation of different types and subtypes of influenza viruses was observed. Of the 1,278 samples
analyzed, 414 (42.6%) were A(H1N1)pdm09, 525 (54.0%) were A(H3N2) and 33 (3.4%) were type-B viruses. Among
A(H1N1)pdm09 isolates, 2 (0.5%) were oseltamivir-resistant and all were amantadine-resistant. Among A(H3N2) viruses, 520
(99.0%) were amantadine-resistant. Sequence and phylogenetic analyses of A(H1N1)pdm09 viruses from the post-pandemic
period showed further evolution from the pandemic period viruses. For viruses that circulated in 2010–2011, strain
predominance varied among prefectures. In Hokkaido, Niigata, Gunma and Nagasaki, A(H3N2) viruses (A/Perth/16/2009-like)
were predominant whereas, in Kyoto, Hyogo and Osaka, A(H1N1)pdm09 viruses (A/New_York/10/2009-like) were
predominant. Influenza B Victoria(HA)-Yamagata(NA) reassortant viruses (B/Brisbane/60/2008-like) were predominant while
a small proportion was in Yamagata lineage. Genetic variants with mutations at antigenic sites were identified in
A(H1N1)pdm09, A(H3N2) and type-B viruses in the 2010–2011 season but did not show a change in antigenicity when
compared with respective vaccine strains.
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Introduction
In late March to early April of 2009, a novel influenza virus of
swine origin emerged in humans in Mexico and the USA and
rapidly spread worldwide, prompting the WHO to declare an
influenza pandemic [1–3]. This is the first influenza pandemic
since the A(H3N2) Hong Kong pandemic of 1968. The pandemic
A(H1N1) 2009 virus [A(H1N1)pdm09] was initially found to be
susceptible to neuraminidase inhibitors, oseltamivir and zanami-
vir, but resistant to amantadine [4]. In the course of the pandemic
in the 2009–2010 period, sporadic cases of oseltamivir-resistant
strains were detected around the world [5,6]. Monitoring of the
antiviral resistance of A(H1N1) viruses is important because of the
widespread resistance of seasonal A(H1N1) viruses to oseltamivir
beginning in the 2007–2008 season [7,8]. Drug-resistant pandemic
A(H1N1) viruses that could acquire the ability to be transmitted
efficientlyamong humans posea considerable publichealth concern.
In Japan, the first pandemic influenza case was reported in May
2009 [9]. In mid-June 2009, the pandemic influenza A(H1N1)
virus had spread throughout Japan and by mid-July, all 47
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pandemic stage viruses revealed that the A(H1N1)pdm09 virus
had evolved since its first appearance in the country [11].
Sequence analysis of viruses from the very early phase (May
2009) and from the peak phase (October 2009 to January 2010) of
the pandemic identified distinct mutations in the HA and NA that
clearly differentiate viruses from these two time periods [12].
In this study, we described the circulation patterns and genetic
characteristics of viruses that circulated during the pandemic and
post-pandemic periods. We focused on the comparison of
pandemic influenza A(H1N1) viruses collected in Japan in the
2009–2010 and 2010–2011 seasons. In addition, we performed
genetic analysis on A(H3N2) and influenza B viruses that
cocirculated with the A(H1N1)pdm09 viruses in the 2010–2011
season.
Results
Clinical Background of Patients
Seven hundred thirty three (733) patients with influenza-like
illness who visited outpatient clinics in six prefectures in Japan
(Fukushima, Gunma, Niigata, Kyoto, Hyogo and Nagasaki)
between July 2009 and February 2010, and 1,278 patients in
seven prefectures (Hokkaido, Niigata, Gunma, Kyoto, Hyogo,
Osaka and Nagasaki) from December 2010 to March 2011
participated in our study. Among these patients, 4 from the 2009–
2010 period and 14 from the 2010–2011 period were hospitalized
after the initial assessment of the severity of infection at the
outpatient clinic (data not shown). All of the hospitalized patients
from the two periods fully recovered. There were no patients with
lethal infection.
Laboratory Surveillance of Influenza Viruses
Of the 733 respiratory specimens that were collected from
patients with influenza-like illness in the 2009–2010 season, 601
A(H1N1)pdm09 viruses (85.4%) were isolated, as confirmed by the
real-time PCR assays (Table 1). A part of the samples were verified
by hemagglutination inhibition (HI) test. A(H1N1)pdm09 influen-
za virus activity peaked in November 2009 (week 47) (Figure 1)
which was 2–3 months earlier than in previous years. No other
type or subtype of influenza viruses was detected during this
period. The pandemic A(H1N1) 2009 virus had completely
replaced the seasonal A(H1N1) virus in the areas studied within
the surveillance period.
Of the 1,278 respiratory specimens that were collected in the
2010–2011 season 972 (76.1%) viruses were isolated. There was
cocirculation of different types and subtypes of influenza viruses in
this season and were distributed as follows: 414 A(H1N1)pdm09
(42.6%), 525 A(H3N2) (54.0%) and 33 influenza B (3.4%) viruses
(Table 1). There were no influenza B viruses detected in
Hokkaido, Gunma and Osaka prefectures. Pandemic A(H1N1)
2009 virus activity peaked in January (weeks 3 and 4) while
A(H3N2) virus activity peaked in February (week 6) (Figure 1).
There was variability in the influenza virus subtype predomi-
nance in each prefecture. A(H3N2) viruses were predominant in
Hokkaido, Niigata and Gunma prefectures in the northern area of
Japan, as well as in Nagasaki in the south. A(H1N1)pdm09 viruses
were predominant in prefectures in the Kansai area of western
Japan: Kyoto, Hyogo and Osaka (Table 1, Figure 2).
Among influenza B viruses, 31 out of 33 (93.9%) isolates belong
to the Victoria lineage and 2 out of 33 (6.1%) isolates belong to the
Yamagata lineage, according to cycling probe real time PCR
results (Table 1).
Detection of H275Y Mutation in the NA
All of the 601 A(H1N1)pdm09 viruses from the 2009–2010
period showed possession of H275 (wild-type) in the neuramin-
idase (NA) by screening with cycling probe real-time PCR and/
or by genetic sequencing. These results suggested possible
susceptibility to oseltamivir among the collected specimens.
In the 2010–2011 season, 2 out of 414 (0.5%) isolates harbor
the H275Y mutation in NA as shown by cycling probe assay
and sequencing. These viruses were from primary respiratory
specimens of patients with no prior treatment of oseltamivir.
Detection of S31N Mutation in the M2
All of the 1,015 A(H1N1)pdm09 isolates in the two seasons were
tested for the presence of M2-S31N substitution that confers
resistance to amantadine using the cycling probe real time PCR
method. All but two viruses possessed the M2-S31N change: A/
Nagasaki/09N079/2009 and A/Kyoto/09K084/2009 had serine
(AGT) at position 31 (as confirmed by sequencing of the
transmembrane domain of the M2 gene) suggesting susceptibility
to amantadine. All A(H1N1)pdm09 viruses from the 2010–2011
season harbor the S31N mutation in M2 (Table 1).
Among the A(H3N2) isolates, 520/525 (99.0%) had the M2-
S31N substitution according to cycling probe real time PCR
results (Table 1), suggesting resistance to amantadine.
Phylogenetic Analysis
a. Pandemic influenza A (H1N1) 2009. Sequence and
phylogenetic analyses of the hemagglutinin (HA) and neuramin-
idase (NA) genes of 81 pandemic influenza A(H1N1) viruses from
the 2009–2010 season and 55 from the 2010–2011 season were
performed.
In the 2009–2010 season, 80 out of 81 (98.8%) isolates had the
S203T mutation in the HA that characterizes cluster 2 viruses
[13]. These viruses were A/New York/10/2009-like (Figure 3).
One isolate, A/Nagasaki/09N083/2009, had serine (S) at amino
acid position 203, belonged to cluster 1 and was related to the
vaccine strain A/California/07/2009. On the other hand, all
isolates had the cluster 2-characteristic N248D amino acid
substitution in the NA. In the 2010–2011 season, HA and NA
phylogenies showed that all 55 A(H1N1)pdm09 viruses belonged
to cluster 2 (Figure 3).
A(H1N1)pdm09 viruses from the 2009–2010 season were
located near the trunk of the HA phylogenetic tree. Comparison
of the HA gene of the A(H1N1)pdm09 viruses with the vaccine
strain (A/California/7/2009) showed 2–14 amino acid mutations.
Among these mutations, 5 are located in antigenic sites Ca
(G170E, S203T, R205K and D222E) and Cb (L70F) [14]
(Figure 3A, Figure 4A). A(H1N1)pdm09 viruses from the 2010–
2011 season exhibited additional amino acid changes in the HA
from the previous season’s strains. Amino acid substitutions S185T
and A197T were observed in fifty-three (53) isolates analyzed.
Amino acid mutations A134T, A141S, S183P and I295V were
detected in two (2) isolates. When compared with the vaccine
strain, 4–14 amino acid mutations were identified. Several of these
mutations are localized in antigenic sites Ca (A141S, G140E,
I166V and E235K), Sa (K153T, K160M, K163N and K163T)
and Sb (S185T and A186T) (Figure 3A, Figure 4A). HI test with
selected strains showed similar antigenicity with the vaccine strain
despite several amino acid changes at putative antigenic sites
(Table S1).
An amino acid change from aspartic acid (D) to glutamic
acid (E) was observed at residue 222 in the HA in 6 isolates
from the 2009–2010 season. However, this amino acid
substitution was not found in 2010–2011 isolates. Glycine (G)
Pandemic and Post-Pandemic Human Influenza Viruses
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were previously reported to be associated with severe illness
[15,16], were not observed among the isolates from both
seasons.
The NA phylogenetic tree was generally congruent with that
of the HA (Figure 3B). Comparison of the NA gene of
A(H1N1)pdm09 viruses with the vaccine strain showed 2–7
amino acid susbstitutions among isolates in the 2009–2010
season and 3–12 substitutions in the 2010–2011 season. The
2010–2011 season viruses were closely related to a strain from
the previous season, A/Kyoto/09K033/2009, and had the
characteristic amino acid substitutions V241I, N44S and N369K
[17] (Figure 3B, Figure 5A). No mutations were found in the
antigenic sites.
Two (2) oseltamivir resistant strains with the H275Y mutation in
the NA collected in 2010–2011 were located in the same branch
in the NA phylogeny. However, these two strains were found in
different branches in the HA phylogeny (Figure 3).
Two (2) amantadine-sensitive strains collected in 2009–2010
were distributed in different branches in both HA and NA
Figure 1. Number of influenza cases per week that were tested positive using the cycling probe real-time PCR method in the 2009–
2010 and 2010–2011 seasons. The figure shows two influenza periods, the pandemic period (2009–2010) and the post-pandemic period (2010–
2011). In 2009–2010, only influenza A(H1N1)pdm09 viruses were detected and its activity peaked at week 47 (November). In 2010–2011, influenza
A(H1N1)pdm09, A(H3N2), and type-B viruses were detected. Activity of A(H1N1)pdm09 viruses peaked at week 3 (January) while activity of A(H3N2)
viruses peaked at week 6 (February). Sporadic cases of influenza B were observed.
doi:10.1371/journal.pone.0036455.g001
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clustered with the A(H1N1)pdm09 clade but not with the
European avian-like H1N1, triple reassortant H1N2 or classical
swine clades, suggesting no evidence of reassortment from other
swine lineages (Figure S1).
b. Influenza A(H3N2). The hemagglutinin (HA) and neur-
aminidase (NA) genes of 71 A(H3N2) viruses from the 2010–2011
season were analyzed. The HA and NA phylogenies showed that 48
isolates belonged to the A/Perth/16/2009 (Perth16) clade and 23
isolates belonged to the A/Victoria/208/2009 (Vic208) clade
(Figure 6). When compared with the vaccine strain, A/Perth/16/
2009, A(H3N2) isolates had 2–17 amino acid mutations in the HA,
9 of which are found in antigenic sites A (N144K), B (P162S), C
(E50K, D53N and E280A/S/T) and E (I260M and R261Q) [18]
(Figure 4B, Figure 6A). The Perth16 clade was characterized by 5
amino acid mutations at residues 62, 144, 162, 260 and 261 when
compared with the vaccine strain. Of these, 4 are found at antigenic
sites A (N144K), B (P162S) and E (I260M and R261Q). Selected
Perth16 clade viruses showed similar antigenicity to the vaccine
strain in the HI test (Table S2).The Vic208 clade was characterized
by the amino acid change T212A located in antigenic site C.
Interestingly, geographical and temporal clustering was observed
Table 1. Detection of influenza virus type, subtype and antiviral-resistance by cycling probe real time PCR.
2009–2010 season 2010–2011 season
Prefecture
No. of
samples Influenza A
No. of
samples Influenza A Influenza B
A(H1N1)pdm09 OsR* AmR** A(H1N1)pdm09 OsR* AmR** A(H3N2) AmR**
Hokkaido - - - - 80 6 0 6 38 38 0
F u k u s h i m a 9 35 1 0 5 1 -- -----
Gunma 31 27 0 27 46 5 0 5 35 35 0
Niigata 100 74 0 74 555 65 0 65 295 295 15
Kyoto 306 295 0 294 328 217 1 217 59 54 14
Osaka - - - - 50 21 0 21 6 6 0
Hyogo 66 60 0 60 99 59 1 59 33 33 3
Nagasaki 137 94 0 93 120 41 0 41 59 59 1
TOTAL 733 601 0 (0.0%)
a 599
(99.7%)
a
1278 414 2 (0.5%)
a 414
(100%)
a
525 520
(99.0%)
a
33
*oseltamivir-resistant (OsR): H275Y mutation in NA.
**amantadine-resistant (AmR): S31N mutation in M2.
‘‘-’’ no samples collected.
aPercentage of antiviral resistant viruses in each season.
doi:10.1371/journal.pone.0036455.t001
Figure 2. Geographic distribution of influenza isolates in the 2009–2010 and 2010–2011 seasons in Japan.
doi:10.1371/journal.pone.0036455.g002
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Hokkaido, Gunma, Niigata and Nagasaki from December 2010,
while Vic208 clade viruses was observed only in the Kansai area
(Kyoto, Osaka and Hyogo) after January 2011.
Mutations in the NA of A(H3N2) viruses ranged from 4–17
amino acid residues when compared with the vaccine strain
(Figure 6B). Of these, 4 are located in antigenic sites F’ (L338F), I’
(K369T) and K’ (R400K and N402D) [19] (Figure 5B, Figure 6B).
Amino acid changes D127N, I307M, L338F and N342D are
unique to the Perth16 clade. The L338F substitution is located in
antigenic site F’. Amino acid substitutions K369T, I464L and
S367N are unique to the Vic208 clade strains, with K369T found
in antigenic site I’.
c. Influenza B viruses. Genetic analysis of the HA and NA
sequences of 29 influenza B viruses was performed. The HA
phylogeny showed that 27 viruses belonged to the Victoria lineage;
26 viruses were closely related to the vaccine strain, B/Brisbane/
60/2008 (Brisbane60) and 1 virus (B/Niigata/10F478/2011) was
closely related to an earlier vaccine strain, B/Malaysia/2506/
2004. The remaining 2 viruses belonged to the Yamagata-lineage
and were B/Bangladesh/3333/2007-like (Bangladesh3333)
(Figure 7A). Within the Brisbane60 clade of the Victoria lineage,
6 amino acid substitutions were identified when compared with
the vaccine strain; 4 of which are found in antigenic sites A
(A127T and I146V), B (K165N and K209N) [20] (Figure 4C). The
amino acid change I146V was found in all Brisbane60 clade
Figure 3. Phylogenetic analysis of the A) HA1 fragment of hemagglutinin, HA gene (829nt) and B) neuraminidase, NA gene
(1,413nt) of A(H1N1)pdm isolates. Trees were constructed using the Neighbor-Joining method. Numbers at the nodes indicate confidence levels
of bootstrap analysis with 1,000 replicates as percentage value. Amino acid substitutions that characterized a particular branch are indicated on the
left side node. Vaccine strains are italicized and in red. Reference strains are boldfaced. Sequences from 2009–2010 are in pink and sequences from
2010–2011 are in blue. Oseltamivir-resistant strains (OsR) are indicated with filled circles (N) and amantadine-sensitive strains (AmS) are indicated
with filled triangles (m).
doi:10.1371/journal.pone.0036455.g003
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lineage, 8 amino acid changes were found when compared with
the vaccine strain, B/Florida/4/2006. Three of these substitutions
are located in antigenic sites A (S150I), B (N165Y) and D (S229D)
(Figure 4C). Viruses from both clades showed compatible
antigenicities when compared with their respective vaccine strains
(Table S3).
The NA phylogeny showed that all viruses belonged to the
Yamagata-lineage but the clustering into two distinct groups was
similar to that of the HA (Figure 7B). Within the Brisbane60 clade,
13 amino acid changes were observed; of which, 2 are found in
antigenic sites F’ (N329D) and G (N340D) (Figure 5C). Within the
Bangladesh3333 clade, 8 amino acid substitutions were identified
wherein 1 amino acid change is located in the antigenic site G’
(D340N) (Figure 5C, Figure 7B).
Discussion
The pandemic influenza A(H1N1) virus first appeared in Japan
in May 2009 and reached the pandemic stage in June 2009 [9]. In
the course of the surveillance study we conducted during the
pandemic period, A(H1N1)pdm09 viruses were the only circulat-
ing strains detected. The seasonal A(H1N1) virus that was
predominant until the 2008–2009 season was not detected in
Japan after week 36 of 2009 [21]. In August 2010, the WHO
announced that the A(H1N1)pdm09 virus had moved into the
post-pandemic period. It continued to circulate worldwide in the
2010–2011 season. In contrast to the pattern we observed during
the pandemic period, the A(H1N1)pdm09 virus cocirculated with
other influenza viruses, namely A(H3N2) and type-B viruses. The
percentage of A(H1N1)pdm09 viruses that were isolated in our
surveillance study went from 100% during the pandemic period
(2009–2010) to 43% in the post-pandemic period (2010–2011).
The decrease in the number of clinical cases may be attributed to
an increase in antibody levels against the A(H1N1)pdm09 virus in
the community [22,23]. This is supported by the results of the
sero-surveillance studies conducted by the Infectious Disease
Surveillance Center in 2009 and in 2010 that showed a substantial
increase in the antibody levels of those surveyed in 2010, reaching
a high prevalence rate of over 50% among school-aged children,
when compared with the antibody levels in 2009 (prevalence rate
Figure 4. Observed mutations in the antigenic sites of HA of influenza virus isolates in Japan, 2009–2010 and 2010–2011. Three-
dimensional structures of trimeric HA were downloaded from the Protein Data Bank (RCSB PDB, http://www.pdb.org) [44] and visualized using PyMol
(http:www.pymol.org). (A) The amino acid differences in the antigenic sites of HA between Japanese A(H1N1)pdm09 isolates and vaccine strain, A/
California/07/2009 were compared. Amino acid substitutions at G140E, A141S, I166V, G170E, S203T, R203T, D222E, E235K are located in antigenic site
Ca (orange); L70F is located in antigenic site Cb (blue); K153T, K160M, K163T/N in antigenic site Sa (magenta); and S185T, A186T in antigenic site Sb
(cyan). Amino acid changes outside the antigenic sites are shown in yellow. PDB entry: 3LZG. (B) HA antigenic site mutations between Japanese
A(H3N2) isolates and vaccine strain, A/Perth/16/2009 were compared. N144K mutation is localized in antigenic site A (red); P162S in antigenic site B
(orange); G50E/K. T212A, and E280A/S/T are localized in antigenic site C (green); I260M and R261Q are located in antigenic site E (blue). PDB entry:
1MQL (C) Amino acid substitutions in the HA antigenic sites of influenza B isolates in Japan and vaccine strain, B/Brisbane/60/2008 were compared.
Mutations at A127T, V146I, and S150I are localized at antigenic site A (red); N165K/Y and K209N are located in antigenic site B (orange); and S229D is
located in antigenic site D (violet). PDB entry: 2RFT.
doi:10.1371/journal.pone.0036455.g004
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html, [Japanese]).
Influenza A(H3N2) was the predominant influenza type-A virus
that caused illness in the 2010–2011 season in our study. Strain
predominance varied among prefectures but geographic clustering
was evident. Prefectures in northern Japan had 4 to 7 times more
A(H3N2) viruses detected than A(H1N1)pdm09 viruses. Prefec-
tures in the Kansai area (Kyoto, Hyogo and Osaka) had about 2 to
4 times more A(H1N1)pdm09 viruses detected than A(H3N2)
viruses. Influenza virus peak activity also varied among the type-A
viruses. The A(H1N1)pdm09 virus activity peaked in late January
whereas A(H3N2) virus activity peaked in mid-February. We
could not assess the peak of influenza B due to the termination of
the study in early March. According to the National Influenza
Surveillance in Japan, more influenza B viruses than influenza A
viruses were detected after week 12 until week 20 (http://idsc.nih.
go.jp/iasr/influ-e.html) in Japan.
Characteristics of A(H1N1)pdm09 Viruses
In the first year of pandemic (2009–2010), we did not detect any
oseltamivir-resistant A(H1N1)pdm09 viruses. In the following
season, we detected two (2) A(H1N1)pdm09 viruses (0.5%
prevalence) that possessed the H275Y substitution in the NA.
These two isolates came from patients who had not received
oseltamivir treatment, live in different areas and were infected at
different times. There was no epidemiological link established
between the two cases. These naturally-occurring oseltamivir-
resistant A(H1N1)pdm09 viruses in untreated patients were
previously reported in Hong Kong and Vietnam [24,25]. The
reported oseltamivir-resistant A(H1N1)pdm09 viruses in Japan in
the 2009–2010 season mostly came from patients who received
oseltamivir as treatment and as prophylaxis, which suggested
sporadic emergence from oseltamivir-sensitive A(H1N1)pdm09
viruses due to selective drug pressure [26]. The two oseltamivir-
resistant A(H1N1)pdm09 strains in this study showed a clustering in
the NA phylogeny due to the H275Y amino acid substitution, but
not in the HA phylogeny. In contrast, the oseltamivir-resistant
seasonal A(H1N1) viruses isolated in the 2008–2009 season showed
a clustering in both the HA and NA phylogenies with signature
amino acid changes other than the H275Y mutation in Japan [8].
The low prevalence of oseltamivir-resistant A(H1N1)pdm09 viruses
in this study suggests limited community transmission.
The A(H1N1)pdm09 virus contains the M gene of the Eurasian
swine lineage (originally derived from an avian influenza virus) and
has the genetic marker (S31N in M2) for resistance to amantadine
[27]. In this study, two A(H1N1)pdm09 viruses from the 2009–
2010 period have serine (S) at residue 31 of the M2. These viruses
were susceptible to amantadine based on the phenotypic assay
TCID50 (results not shown). DNA sequencing of the M gene of
these two viruses showed that the sensitivity was due to a
spontaneous mutation in the M2 segment and was not due to a
reassortment with an amantadine-sensitive gene segment. From a
CDC report [28], it can be inferred that 0.2% (4/1899) of
A(H1N1)pdm09 viruses tested were also sensitive to amantadine
which suggests that these rare amantadine-sensitive viruses were in
circulation in the 2009–2010 season. However, in the following
season amantadine-sensitive A(H1N1)pdm09 viruses were not
detected in our study.
Based on the HA and NA sequence data of viruses collected
within the pandemic period from July 2009 to February 2010,
Figure 5. Amino acid mutations differences in the NA of influenza virus isolates in Japan, 2009–2010 and 2010–2011. Three-
dimensional structures of monomeric NA were downloaded from the Protein Data Bank (RCSB PDB, http://www.pdb.org) [44] and visualized using
PyMol (http:www.pymol.org). The top view of the NA is shown. (A) The amino acid differences between A(H1N1)pdm09 isolates in Japan and vaccine
strain, A/California/07/2009 were compared. Amino acid substitutions V241I and N369K are shown in yellow. These amino acid changes are located
outside the antigenic sites but are phylogenetically relevant. PDB entry: 3NSS. (B) Antigenic site mutations between Japanese A(H3N2) isolates and
vaccine strain, A/Perth/16/2009 were compared. L338F mutation is located in antigenic site F’ (olive); K369T is localized in antigenic site I’; and R400K
and N402D are located in antigenic site K’. PDB entry: 1IVG (C) Amino acid substitutions in the NA antigenic sites of Japanese influenza B isolates and
vaccine strain, B/Brisbane/60/2008 were compared. Mutations at N329D is localized at antigenic site F’ (olive); and D340N/D is located in antigenic
site G’ (violet). PDB entry: 1INF.
doi:10.1371/journal.pone.0036455.g005
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vaccine strain, A/California/07/2009 and belong to cluster 2.
The signature amino acid changes, HA-S203T and NA-N248D,
of cluster 2 viruses that differentiate it from early pandemic cluster
1 viruses continued to persist throughout the duration of the
pandemic and into the 2010–2011 season. One isolate, A/
Nagasaki/09N083/2009, collected in November 2009 has a
cluster 1 HA but a cluster 2 NA. This virus belongs to cluster
1.2 which mostly contained viruses from Japan isolated during the
early phase of the pandemic [13].
Sequence analysis of A(H1N1)pdm09 viruses of the 2010–2011
season showed further evolution from viruses of the 2009–2010
season. These viruses were closely related to the previous season
strains, A/Nagasaki/09N114/2009 and A/Fukushima/09FY090/
2010. Viruses with the amino acid substitutions S185T and A197T
had the greatest expansion and geographic spread. Structural
analysis showed that S185T is found in the antigenic site Sb, which
is located on the globular head of the HA (Figure 4A). The amino
acid substitution A197T is found in almost all of the viruses from
the 2010–2011 season and is located next to the antigenic site Sb.
Figure 6. Phylogenetic analysis of the A) HA1 fragment of hemagglutinin, HA gene (954nt) and B) neuraminidase, NA gene
(1,388nt) of influenza A(H3N2) isolates. Trees were constructed using the Neighbor-Joining method. Numbers at the nodes indicate confidence
levels of bootstrap analysis with 1,000 replicates as percentage value. Amino acid substitutions that characterized a particular branch are indicated on
the left side node. Vaccine strains are italicized and in red. Reference strains are boldfaced.
doi:10.1371/journal.pone.0036455.g006
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of viruses analyzed, is located next to the antigenic site Ca. In a
previous report [29], two (2) viruses with the S143G substitution
were observed to have reduced antigenicity against the A/
California/07/2009 vaccine virus in the HI test. However,
selected A(H1N1)pdm09 viruses with the S143G mutation from
our study did not show a reduction in the HI titer when compared
with the vaccine strain. These mutations in the HA did not
contribute to a change in antigenicity of the A(H1N1)pdm09
viruses in our study.
The amino acid substitutions HA-D222G/N in
A(H1N1)pdm09 viruses were previously associated with severe
infection [15,16]. These mutations were not detected among the
81 isolates analyzed from the 2009–2010 season. Instead, a D222E
substitution was found in 6 isolates representing 1.0% of viruses
from the 2009–2010 period. This mutation was observed to be not
associated with severe infection [16]. In the 2010–2011 season, the
D222E mutation did not persist and all viruses had the wild-type
genotype. The D222G/N mutations were not found in viruses in
this season.
A new amino acid mutation in the NA of A(H1N1)pdm09
viruses associated with reduced susceptibility to neuraminidase
inhibitors were recently reported. A mild reduction in oseltamivir
and zanamivir susceptibility was observed in viruses from Oceania
and Southeast Asia with the S247N (serine to asparagine) mutation
[30]. We have not found this mutation in the viruses we analyzed.
Characteristics of A(H3N2) Viruses
Our results showed the prevalence of amantadine-resistant
A(H3N2) viruses is high (99%) in the 2010–2011 season. The trend
of high prevalence of amantadine resistance among A(H3N2)
viruses was observed in Japan after the 2005–2006 season in
Japan, reaching 100% prevalence in the 2008–2009 season [8,31].
However, in the post- pandemic (2010–2011) season, we detected
5 A(H3N2) viruses (1%) with the amantadine-susceptible S31
genotype in M2. Additional studies are needed to fully elucidate
the genetic evolution of A(H3N2) viruses in relation to drug
resistance or susceptibility.
Genetic analysis showed there were two groups of A(H3N2)
viruses detected in the 2010–2011 season, A/Perth/16/2009-like
and A/Victoria/208/2009-like [32]. However, A/Perth/16/
2009-like viruses were mainly detected in prefectures where
A(H3N2) viruses predominated in the beginning of the 2010–2011
season in December (Hokkaido and Nagasaki), while A/Victoria/
208/2009-like viruses were detected in prefectures where
A(H1N1)pdm09 predominated and started to circulate only in
January (Hyogo and Osaka). These findings suggest that the
timing and circulation patterns of the two clades were different
and that these viruses may have been transmitted to Japan from
other countries at different timing and routes.
Our sequence analysis showed additional mutations in the HA
of 2010–2011 viruses from previously circulating strains. Several
amino acid substitutions in the putative antigenic sites in HA and
Figure 7. Phylogenetic analysis of the A) HA1 fragment of hemagglutinin, HA gene (885nt) and B) neuraminidase, NA gene
(1,404nt) of influenza B viruses. Trees were constructed using the Neighbor-Joining method. Numbers at the nodes indicate confidence levels of
bootstrap analysis with 1,000 replicates as percentage value. Amino acid substitutions that characterized a particular branch are indicated on the left
side node. Vaccine strains are italicized and in red. Reference strains are boldfaced.
doi:10.1371/journal.pone.0036455.g007
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compared with the vaccine strain, A/Perth/16/2009. The
mutations in the HA may have contributed to the reduced
antigenicity against the vaccine strain of some Vic208 clade viruses
[29]. Only Perth16 clade viruses underwent HI testing in our study
and these viruses did not show a reduction in titer against the
vaccine strain. Although all viruses tested were A/Perth/16/2009-
like, these viruses have similar antigenicities with A/Victoria/208/
2009-like viruses as previously reported [33].
Characteristics of Influenza B Viruses
There was cocirculation of Victoria-lineage and Yamagata
lineage influenza B viruses in the 2010–2011 season. Most of the
influenza viruses isolated belong to the Victoria lineage in the HA
and were similar to the vaccine strain, B/Brisbane/60/2008.
These reassortant Victoria lineage viruses that had a Yamagata
lineage NA have been stably circulating worldwide since its
emergence in 2002 [34]. The evolution of the NA is parallel with
that of the HA as evidenced in the similar clustering of viruses in
the phylogenies although the NA belongs to the same Yamagata
lineage.
In summary, all three predominantly circulating viruses in the
2010–2011 season demonstrated genetic variability from the
previously circulating strains but were closely related to the 3
strains recommended by the WHO to be included in the vaccine
for the 2011–2012 influenza season in the northern hemisphere:
an A/California/7/2009-like virus, an A/Perth/16/2009-like
virus and a B/Brisbane/60/2008-like virus [35]. In addition, only
a small percentage of influenza A viruses tested was resistant to
oseltamivir but almost all were resistant to amantadine.
It remains to be seen whether the pandemic A(H1N1) 2009
virus will follow the path of other pandemic viruses such as that of
the Asian influenza A(H2N2) virus which survived shortly in the
human population and disappeared 11 years after its emergence
[36] or that of the Hong Kong influenza A(H3N2) virus which 43
years later still remains an important cause of influenza illness in
humans [36].
Materials and Methods
Study Design
Eligible patients to this study were those who visited outpatient
clinics presented with influenza-like illness symptoms (fever of
$37.5uC, cough and/or sore throat) and had not been treated
with amantadine, oseltamivir or zanamivir within the previous
four weeks. The study period was between July 30, 2009 and
March 22, 2011. The Niigata University Division of International
Health (Public Health) supplied viral transport media to clinicians
participating in the Japanese Influenza Collaborative Study Group
(18 clinics in eight Prefectures in Japan: Hokkaido, Fukushima,
Gunma, Niigata, Kyoto, Hyogo, Osaka and Nagasaki Prefectures).
Clinicians performed an influenza rapid diagnostic test, mainly by
using the Quick-Ex Flu kit (Denka Seiken, Co. Ltd., Tokyo,
Japan), on the first respiratory specimen, and collected a second
respiratory specimen regardless of the rapid test results. The
samples were stored in viral transport media for #72 hours at 4uC
before shipment to our laboratory. Informed written consent was
obtained from the patient or the patient’s guardian prior to
specimen collection. The study was approved by the medical
faculty ethics committee of the Niigata University Graduate
School of Medical and Dental Sciences.
Virus Isolation and Characterization
About 100 ml of nasopharyngeal sample was inoculated onto
Madin-Darby canine kidney (MDCK) cells. MDCK cell lines were
kindly provided by Dr. Hidekazu Nishimura of Virus Center,
Sendai National Medical Center, Miyagi Prefecture, Japan and
were maintained as previously described [37]. Cultures were
monitored for cytopathic effect (CPE) for 3–7 days. All isolates
were typed and subtyped by cycling probe real-time PCR assays.
Selected influenza isolates underwent a hemagglutination inhibi-
tion (HI) assay using guinea pig red blood cells (Toyo Bio, Tokyo,
Japan) and commercially available influenza vaccine strain
antisera: A/California/7/2009 (pandemic H1N1), A/Brisbane/
59/2007 (seasonal H1N1), A/Victoria/210/2009 (H3N2), B/
Brisbane/60/2008 (influenza B, Victoria) and B/Florida/4/2006
(influenza B, Yamagata) (Denka Seiken Co., Ltd., Tokyo, Japan).
RNA Extraction and cDNA Synthesis
Total RNA was extracted from 100 ml of clinical specimens and
from 100 mL of viral culture using Extragen II kit (Kainos, Tokyo,
Japan) following manufacturer’s instructions. First-strand cDNA
synthesis was performed using influenza A and B universal primers
[37,38].
Real-time PCR Genotyping of Drug-resistant Strains
Cycling probe real-time PCR screening for mutations in M2
and NA genes that confer resistance to amantadine and
oseltamivir, respectively, was performed on all 1,540 influenza A
virus isolates (2009–2010 and 2010–2011) using fluorescent-
labeled chimeric RNA-DNA probes and RNaseH (TaKaRa Bio
Inc., Ohtsu, Japan). This assay utilizes a single nucleotide
polymorphism (SNP) which can simultaneously detect amanta-
dine-sensitive (S31) and amantadine-resistant (S31N) viruses as
previously described [39]. Similarly, another single nucleotide
polymorphism which can distinguish between oseltamivir-sensitive
(H275) and oseltamivir-resistant (H275Y) viruses was used as
previously described [40]. SNP typing was performed using
Thermal Cycler Dice Real Time PCR System TP800 (TaKaRa
Bio Inc., Ohtsu, Japan).
Cycling Probe Real-time PCR Method for Influenza B
Samples that were negative for the screening methods for
A(H1N1)pdm09 and A(H3N2) were tested using a cycling probe
real-time PCR method that can distinguish Victoria-lineage and
Yamagata-lineage influenza B viruses according to the HA gene
sequence.
For the influenza B cycling probe real time PCR reaction, a
commercially available cycling probe real time PCR kit, TaKaRa
CycleavePCRHCore Kit (TaKaRa Bio Inc., Ohtsu, Japan) was
used. The PCR reaction was prepared according to the
manufacturer’s instructions and was supplemented with 5 pmol
of each primer (a forward primer, a Victoria lineage-specific
reverse primer and a Yamagata lineage-specific reverse primer),
2.5 pmol of the carboxyfluorescein (FAM)-labeled probe (Victoria
HA gene-specific), 2.5 pmol of the carboxy-X-rhodamine (ROX)-
labeled probe (Yamagata HA gene-specific), and 1 mL of viral
cDNA in a 25 ml reaction volume. PCR amplification and
fluorescence detection were performed on Thermal Cycler Dice
Real Time PCR System TP800 (TaKaRa Bio Inc., Ohtsu, Japan).
Cycling conditions were as follows: denaturation at 95uC for 10
seconds followed by 40 cycles of denaturation at 95uC for 5
seconds, primer annealing at 57uC for 10 seconds, and extension
and subsequent detection of fluorescence at 72uC for 15 seconds
(primers and probes information are available on request).
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The HA and NA genes of 136 A(H1N1)pdm09, 71 A(H3N2)
and 29 influenza B viruses, as well as the M gene of 6
A(H1N1)pdm09 viruses from the 2009–2010 season, were
amplified using gene-specific primers. PCR products were purified
using MSBP Spin PCRapace kit (Invitek GmbH, Berlin,
Germany) and directly sequenced. Sequencing reactions were
carried out using BigDye Terminator v3.1 cycle sequencing kit
(Applied Biosystems, Carlsbad, USA) and sequencing products
were run on an ABI Prism 3100 Genetic Analyzer. Sequences
were assembled using Lasergene SeqMan Pro package version
7.2.1 (DNASTAR, Madison, USA) and assembled sequences were
edited using BioEdit software (http://www.mbio.ncsu.edu/
BioEdit/). Phylogenetic analysis was performed using MEGA 4.0
software [41] (Molecular Evolutionary Genetics Analysis). Best-
fitting trees for the HA and NA genes were constructed by the
Neighbor-Joining method [42] with the maximum composite
likelihood model [43] and bootstrap analysis of 1,000 replicates.
Deduced amino acid sequences were analyzed and changes in the
antigenic sites were compared among isolates with the respective
vaccine strains: A/California/7/2009 (H1N1pdm); A/Perth/16/
2009 (H3N2); and B/Brisbane/60/2008 (influenza B). In this
study, all HA amino acid residues are numbered without the signal
peptide sequence. HA and NA numbering are based on the
respective type and subtype.
GenBank accession numbers of the HA and NA sequences of
Japanese A(H1N1)pdm09 strains from the 2009–2010 season are
CY066017–CY066182 and from the 2010–2011 season are
JN790349–JN790440. The accession numbers for the HA and
NA sequences of A(H3N2) strains from the 2010–2011 season are
JN790441–JN790581, and for the influenza B strains are
JN790295–JN790348. Vaccine strain sequences and supplemental
sequences used for the phylogenetic trees were obtained from the
GISAID EpiFlu
TM Database (www.gisaid.org) and from GenBank
(www.ncbi.nlm.nih.gov/genbank).
Antigenic Site Mapping of HA and NA
HA and NA amino acid sequences of influenza virus isolates in
Japan were compared with the vaccine strains. Identified amino
acid substitutions were mapped to reported HA antigenic sites
[14,18,20] and NA antigenic sites [17,19]. Crystal structures of
HA (PDB entry 3LZG for H1, 1MQL for H3, and 2RFT for type
B) and NA (PDB entry 3NSS for N1, 1IVG for N2, and 1INF for
type B) were downloaded from Protein Data Bank (RCSB PDB,
http://www.pdb.org) [44]. Molecular models were analyzed using
the PyMol software v1.3 (http://www.pymol.org).
Supporting Information
Figure S1 Phylogenetic analysis of the M gene of
amantadine-sensitive A(H1N1)pdm09 viruses. Trees were
constructed using the Neighbor-Joining method. Numbers at the
nodes indicate confidence levels of bootstrap analysis with 1,000
replicates as percentage value. Human A(H1N1)pdm09 strains
from the present study are in bold. Amantadine-sensitive strains
(AmS) are indicated with filled triangles (m). Other viruses
included in the analysis were based on the study by Vijaykrishna
D et al. (2010) [45] and the sequences were obtained from
GenBank. The Japanese swine sequences were also obtained from
GenBank.
(TIF)
Table S1 Hemagglutination inhibition (HI) titer of selected
A(H1N1)pdm09 viruses from the 2010–2011 season.
(XLS)
Table S2 Hemagglutination inhibition (HI) titer of selected
A(H3N2) viruses from the 2010–2011 season.
(XLS)
Table S3 Hemagglutination inhibition (HI) titer of selected
influenza B viruses from the 2010–2011 season.
(XLS)
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